Sharon Benzeno, PhD

Sharon Benzeno, PhD

Chief Commercial Officer, IMatAdaptive Biotechnologies· In proxies 2022–2024

Pay in FY2023-11% from the year before · Adaptive Biotechnologies stock -35.9% the same year

Sharon Benzeno, PhD was paid $2.9M in FY2023 (Dec), down 11%. Adaptive Biotechnologies stock fell 35.9% that year.

Pay$100 in the stock at the end of FY21 → $17
Pay is from the Summary Compensation Table of each Adaptive Biotechnologies proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Adaptive BiotechnologiesPublic company · 4 yr
    • Chief Commercial Officer, IM2022 – Present · 4 yrStock in role +6%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?